Will Osiris's 'overwhelming' data shove Shire's Dermagraft in the mire?
This article was originally published in Scrip
Executive Summary
Shares in Osiris Therapeutics shot up 125% in morning trading on 13 August after the firm announced it has stopped a study of its Grafix cellular wound care product in diabetic foot ulcer because of "overwhelming efficacy." Its stock was trading at $24.01 during the day, up from a closing price on $10.66 on 12 August.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.